肿瘤细胞治疗研究
英文原题：Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
在这项1期试验中，17例转移性检查点抑制剂耐药黑色素瘤患者接受了TILT-123和TIL治疗，未进行预处理化疗或后处理IL-2。
TIL（肿瘤浸润淋巴细胞）（TILs）在转移性黑色素瘤（MM）治疗中有效，但毒性限制了其应用。TILT-123（igrelimogene litadenorepvec）是一种溶瘤腺病毒，复制时可产生白细胞介素-2（IL-2）和肿瘤坏死因子（TNF）。在这项1期试验中，17例转移性检查点抑制剂耐药黑色素瘤患者接受TILT-123和TILs治疗，未进行预处理化疗或后处理IL-2。该治疗安全可行。根据计算机断层扫描（CT），客观缓解率为11.7%（2/17），35%（6/17）观察到疾病控制，包括一例持续>8个月的部分缓解和一例黏膜黑色素瘤患者的持久完全缓解。根据正电子发射断层扫描（PET），7/15（47%）观察到疾病控制，4/15（27%）为轻微或部分缓解。在试验的初始TILT-123单药治疗阶段，CT和PET分别观察到6/17（35%）和10/16（63%）的疾病控制。该研究显示出良好的耐受性和初步疗效。
Tumor-infiltrating lymphocytes (TILs) are effective in the treatment of metastatic melanoma (MM), but toxicity limits its application. TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus producing interleukin-2 (IL-2) and tumor necrosis factor (TNF) upon replication. In this phase 1 trial, 17 patients with metastatic checkpoint inhibitor-resistant melanoma are treated with TILT-123 and TILs without preconditioning chemotherapy or postconditioning IL-2. The treatment is safe and feasible. According to computed tomography (CT), the objective response rate is 11.7% (2/17) and disease control is observed in 35% (6/17), including a partial response lasting >8 months and a durable complete response in a mucosal melanoma patient. According to positron emission tomography (PET), disease control is observed in 7/15 (47%) with minor or partial responses in 4/15 (27%). In the initial TILT-123 monotherapy phase of the trial, disease control is observed in 6/17 (35%) and 10/16 (63%) in CT and PET, respectively. The study demonstrates good tolerability and preliminary efficacy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
